<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385382</url>
  </required_header>
  <id_info>
    <org_study_id>UChieti</org_study_id>
    <nct_id>NCT03385382</nct_id>
  </id_info>
  <brief_title>Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema</brief_title>
  <acronym>LED</acronym>
  <official_title>Macular Thickness and Vessel Density Changes After Dexamethasone Implant and Ranibizumab Intravitreal Injection in Diabetic Macular Edema: 6-month Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients
      with diabetic macular edema were recruited at the Ophthalmologic Clinic of University &quot;G.
      d'Annunzio&quot;, Chieti-Pescara, Italy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2016</start_date>
  <completion_date type="Actual">June 27, 2017</completion_date>
  <primary_completion_date type="Actual">June 27, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Central macular thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Decrease of macular thickness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Increase of mean visual acuity</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <description>Patients with diabetic macular edema receiving dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <description>Patients with diabetic macular edema receiving ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant 0.7 mg</intervention_name>
    <description>Intravitreal Implant of dexamethasone</description>
    <arm_group_label>Dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Injection</intervention_name>
    <description>Injection of ranibizumab</description>
    <arm_group_label>ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with no proliferative moderate DR stage (simplified version of the ETDRS
        classification aimed by the American Academy of Ophthalmology Guidelines Committe) and
        cystoid macular edema type without subretinal fluid component were recruited
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years old

          -  BCVA greater than 0.5 LogMAR in the study eye at baseline examination

          -  Presence of recent DME

          -  CMT &gt; 300Âµm as measured using the SD-OCT at the baseline examination

        Exclusion Criteria:

          -  Any previous ocular surgery in the last 6 months

          -  Laser treatments

          -  Prior ocular trauma

          -  Retinal vascular diseases

          -  Vitreo-retinal interface diseases

          -  Medium lens opacities (according to Lens Opacities Classification System)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G. d'Annunzio University</investigator_affiliation>
    <investigator_full_name>LISA TOTO</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Yes by request to the investigator via email</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

